Titlebook: Organ Directed Toxicities of Anticancer Drugs; Proceedings of the F Miles P. Hacker,John S. Lazo,Thomas R. Tritton Conference proceedings 1

Detrusor-Muscle

書目名稱Organ Directed Toxicities of Anticancer Drugs影響因子(影響力)




書目名稱Organ Directed Toxicities of Anticancer Drugs影響因子(影響力)學(xué)科排名




書目名稱Organ Directed Toxicities of Anticancer Drugs網(wǎng)絡(luò)公開度




書目名稱Organ Directed Toxicities of Anticancer Drugs網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Organ Directed Toxicities of Anticancer Drugs被引頻次




書目名稱Organ Directed Toxicities of Anticancer Drugs被引頻次學(xué)科排名




書目名稱Organ Directed Toxicities of Anticancer Drugs年度引用




書目名稱Organ Directed Toxicities of Anticancer Drugs年度引用學(xué)科排名




書目名稱Organ Directed Toxicities of Anticancer Drugs讀者反饋




書目名稱Organ Directed Toxicities of Anticancer Drugs讀者反饋學(xué)科排名

duplicate

ALLAY

Role of Iron in Anthracycline Actiononly relatively recently that attention has focused on the role of iron chemistry in this process. Interest in this problem is bound to increase as a result of recent clinical and preclinical studies which demonstrate that ICRF-187, an EDTA derivative, effectively prevents doxorubicin-induced cardia

Forage飼料

Role of Reactive Oxygen Production in Doxorubicin Cardiac Toxicity lymphomas, and carcinomas of the breast, lung, and thyroid (1). The clinical usefulness of these drugs may, however, be compromised by the development of a dose related, congestive cardiomyopathy that is sometimes fatal (2). Over the past decade, a substantial body of experimental data has been pub

懶鬼才會衰弱

Adriamycin Cardiac Toxicity — An Assessment of Approaches to Cardiac Monitoring and Cardioprotectionrolonged use could lead to progressive, refractory, irreversible and almost uniformly fatal congestive heart failure has been a major impediment to its more widespread use in the curative treatment of early cancer and to prolonging its use in responding patients with advanced disease.

傳授知識

羊齒

A Trial of ICRF-187 to Selectively Protect Against Chronic Adriamycin Cardiac Toxicity: Rationale ane drugs, particularly doxorubicin (Adriamycin.), constitute some of the most active compounds available to the clinical oncologist. They have activity in both hematologic malignancies and solid tumors. Numerous efforts to improve upon their activity through analogue development or a better dose sche

narcissism

PATRI

Infirm

Bleomycin Induced Lung Injuryoxicity varies widely, from 2 to 40% (1). Risk factors in developing toxicity include age, cumulative dose, use with other cytotoxic drugs, radiation therapy and oxygen (1). The most frequent manifestation of bleomycin induced pulmonary injury is the development of a diffuse alveolar damage frequent